Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Pancreatic Adenocarcinoma Metastatic × Ipilimumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 221 Carcinoma, Non-Small-Cell Lung 70 Carcinoma, Renal Cell 55 Neoplasm Metastasis 45 Neoplasms 40 Prostatic Neoplasms 32 Lung Neoplasms 27 Uveal Melanoma 25 Pancreatic Neoplasms 23 Carcinoma, Hepatocellular 23 Colorectal Neoplasms 22 Brain Neoplasms 21 Sarcoma 20 Breast Neoplasms 20 Squamous Cell Carcinoma of Head and Neck 17 Small Cell Lung Carcinoma 17 Kidney Neoplasms 17 Skin Neoplasms 16 Carcinoma, Transitional Cell 15 Ovarian Neoplasms 14 Diabetes Mellitus, Insulin-Dependent, 12 14 Urinary Bladder Neoplasms 13 Uterine Cervical Neoplasms 12 Triple Negative Breast Neoplasms 12 Mesothelioma 11 Stomach Neoplasms 10 Recurrence 10 Multiple Myeloma 10 Head and Neck Neoplasms 10 Glioblastoma 10

Interventions

spartalizumab 1 sapropterin 1 penpulimab 1 niraparib 1 anlotinib 1 Taxes 1 Leucovorin 1 Ipilimumab 1 IFL protocol 1 Gemcitabine 1 Decitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06747845 2025-09-16

ParpVax2

Abramson Cancer Center at Penn Medicine

Phase 2 Recruiting

Gastrointestinal

Pancreatic Adenocarcinoma Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡